Inflammatory lesions at the 9 bilateral entheses in patients with ankylosing spondylitis at baseline and after 6 months of TNF-α blocking therapy (n = 85). Values are presented as no. patients and no. lesions.
| Total | Bursitis | Effusion | Hypoechogenicity | Thickening | Positive PD | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pts. 0 m/6 m | Lesions 0 m/ 6 m | Pts. 0 m/6 m | Lesions 0 m/6 m | Pts. 0 m/6 m | Lesions 0 m/6 m | Pts. 0 m/6 m | Lesions 0 m/6 m | Pts. 0 m/6 m | Lesions 0 m/6 m | Pts. 0 m/6 m | Lesions 0 m/6 m | |
| Entheses total | 69/63 | 210/180 | 28/30 | 58/57 | 8/1 | 9/1 | 6/6 | 6/6 | 9/7 | 12/12 | 60/52 | 125/104 |
| Plantar fascia | 2/— | 2/— | —/— | —/— | 2/— | 2/— | —/— | —/— | —/— | —/— | —/— | —/— |
| Achilles tendon | 9/6 | 15/8 | 7/3 | 8/4 | —/— | —/— | —/— | —/— | 2/2 | 2/3 | 4/1 | 5/1 |
| Tibial tuberosity | 9/11 | 13/12 | —/— | —/— | 1/1 | 1/1 | 1/— | 1/— | 1/— | 1/— | 9/10 | 10/11 |
| Patellar tendon | 17/21 | 28/37 | 14/17 | 19/28 | 1/— | 1/— | —/— | —/— | —/2 | —/3 | 5/6 | 8/6 |
| Quadriceps tendon | 18/17 | 30/30 | 13/15 | 23/23 | —/— | —/— | —/— | —/— | 1/— | 1/— | 6/5 | 6/7 |
| Pes anserine | 31/35 | 54/61 | 2/2 | 2/2 | 2/— | 3/— | 1/3 | 1/3 | 2/2 | 4/3 | 28/34 | 44/53 |
| Greater trochanter | 12/6 | 19/6 | 4/— | 5/— | —/— | —/— | —/— | —/— | 1/— | 2/— | 8/6 | 12/6 |
| Medial epicondyle | 11/5 | 13/5 | 1/— | 1/— | 1/— | 1/— | —/— | —/— | —/— | —/— | 10/5 | 11/5 |
| Lateral epicondyle | 21/13 | 36/22 | —/— | —/— | 1/— | 1/— | 4/3 | 4/3 | 2/3 | 2/4 | 20/13 | 29/15 |
TNF-α: tumor necrosis factor-α; PD: power Doppler.